Engineered immune cells take on lupus and scleroderma in early trial
NCT ID NCT06375993
First seen Mar 31, 2026 · Last updated Apr 29, 2026 · Updated 2 times
Summary
This early-phase study tests a new treatment called Prula-cel for people with autoimmune diseases like lupus, scleroderma, and vasculitis. Prula-cel uses specially engineered immune cells from a donor to target and attack faulty B cells that drive the disease. The main goals are to find a safe dose and check for side effects in about 180 adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Adicet Clinical Trials
Redwood City, California, 94065, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.